Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value
| Autor: | Xavier Filella, Jose M. Escudero, Martín Velasco, Montserrat Muñoz, Rafael Molina, G. Zanon, Blanca Farrús, Jaume Pahisa, Jose M. Auge |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
medicine.medical_specialty Receptor ErbB-2 medicine.drug_class medicine.medical_treatment CA 15-3 Breast Neoplasms Disease-Free Survival Breast cancer Carcinoembryonic antigen Internal medicine Biomarkers Tumor medicine Humans In patient Receptor Univariate analysis biology business.industry Mucin-1 General Medicine Middle Aged medicine.disease Carcinoembryonic Antigen Estrogen biology.protein Female business Adjuvant |
| Zdroj: | Tumor Biology. 31:171-180 |
| ISSN: | 1423-0380 1010-4283 |
| DOI: | 10.1007/s13277-010-0025-9 |
| Popis: | Tumor markers were studied in the sera of 883 untreated patients with primary breast cancer diagnosed between 1989 and 2007. Abnormal human epidermal growth factor receptor 2 (HER-2)/neu levels (>15 ng/mL) were found in 9.5%, carcinoembryonic antigen (CEA) in 15.9%, and cancer antigen (CA) 15.3 in 19.7% of the patients. One or more tumor markers were abnormal in 305 (34.5%) of the 883 studied patients. Significantly higher serum HER-2/neu levels were found in patients with tissue overexpression of this oncoprotein (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink